Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 10-12-2022 | Thyroid Cancer | Original Article

[¹⁸F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[¹⁸F]FDG PET/CT

Authors: Xingyu Mu, Xiaoxue Huang, Zewen Jiang, Meng Li, Lulu Jia, Zhongyuan Lv, Wei Fu, Jingsong Mao

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2023

Abstract

Purpose

This study aimed to assess the diagnostic performance of [¹⁸F]FAPI-42 PET/CT and compare it with that of 2-[¹⁸F]FDG PET/CT in patients with differentiated thyroid cancer (DTC) with biochemical elevations in Tg or anti-Tg antibodies.

Methods

A total of 42 patients with DTC with biochemical elevations in Tg or anti-Tg antibodies underwent [¹⁸F]FAPI-42 PET/CT as part of this study; of which, 11 additionally underwent 2-[¹⁸F]FDG PET/CT within 7 days. Images were semi-quantitatively and visually interpreted, and the quantity, location, and uptake values of lesions were noted. The diagnostic capacity of [¹⁸F]FAPI-42 PET/CT and biomarkers affecting the uptake of [¹⁸F]FAPI-42 were evaluated. In addition, the diagnostic performance and uptake of [¹⁸F]FAPI-42 and 2-[¹⁸F]FDG were compared, and the correlation between lesion diameter and quantitative parameters was investigated.

Results

A total of 161 lesions were detected in 27 (64%) patients on [¹⁸F]FAPI-42 PET/CT. FAPI-positive local recurrence showed the highest uptake intensity, followed by lymphatic, other site-associated (bone and pleura), and pulmonary lesions (mean SUV_max, 4.7 versus 3.7 versus 3.0 versus 2.2, respectively; P < 0.0001). The levels of TSH, Tg, and Tg-Ab did not affect the uptake value of lesions (median SUV_max: 2.4 versus 3.2, P = 0.56; 2.9 versus 2.4, P = 0.0935; 2.8 versus 2.6, P = 0.0525, respectively). A total of 90 positive lesions were detected in 7 patients using both modalities. All positive lesions showed statistically higher uptake of 2-[¹⁸F]FDG than that of [¹⁸F]FAPI-42 (SUV_max, 2.6 versus 2.1; P = 0.026). However, the SUV_max of [¹⁸F]FAPI-42 was higher than that of 2-[¹⁸F]FDG in local recurrences and lymphatic lesions (SUV_max, 4.2 versus 2.9 and 3.9 versus 3.4, respectively; P > 0.05).

Conclusion

[¹⁸F]FAPI-42 can be used for detecting lesions and reflecting FAP expression during local recurrence and metastasis in patients with DTC with biochemical elevations in Tg or anti-Tg antibodies. The diagnostic performance of [¹⁸F]FAPI-42 PET/CT is comparable with that of 2-[¹⁸F]FDG PET/CT in such patients.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, et al. Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer. J Clin Oncol. 2018;36:438–45. https://doi.org/10.1200/JCO.2017.74.5497.CrossRefPubMed

Hung ML, Wu JX, Li N, Livhits MJ, Yeh MW. Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer. JAMA Surg. 2018;153:1098–104. https://doi.org/10.1001/jamasurg.2018.2659.CrossRefPubMedPubMedCentral

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentral

Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–63. https://doi.org/10.1002/prca.201300095.CrossRefPubMed

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med Off Publ Soc Nucl Med. 2019;60:801–5. https://doi.org/10.2967/jnumed.119.227967.CrossRef

Sun WY, Jung WH, Koo JS. Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma. Tumour Biol. 2016;37:8197–207. https://doi.org/10.1007/s13277-015-4684-4.CrossRefPubMed

Wen S, Qu N, Ma B, Wang X, Luo Y, Xu W, et al. Cancer-associated fibroblasts positively correlate with dedifferentiation and aggressiveness of thyroid cancer. Onco Targets Ther. 2021;14:1205–17. https://doi.org/10.2147/OTT.S294725.CrossRefPubMedPubMedCentral

Ballal S, Yadav MP, Moon ES, Roesch F, Kumari S, Agarwal S, et al. Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study. Thyroid. 2022;32:65–77. https://doi.org/10.1089/thy.2021.0412.CrossRefPubMed

10.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68 Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.CrossRefPubMedPubMedCentral

11.

Fu H, Wu J, Huang J, Sun L, Wu H, Guo W, et al. (68)Ga fibroblast activation protein inhibitor PET/CT in the detection of metastatic thyroid cancer: comparison with (18)F-FDG PET/CT. Radiology. 2022;304:397–405. https://doi.org/10.1148/radiol.212430.CrossRefPubMed

12.

Chen Y, Zheng S, Zhang J, Yao S, Miao W. Pleural metastasis of papillary thyroid cancer depicted by 68Ga-FAPI PET/CT. Clin Nucl Med. 2022;47:467–8. https://doi.org/10.1097/RLU.0000000000004038.CrossRefPubMed

13.

Wu J, Ou L, Zhang C. Comparison of (68)Ga-FAPI and (18)F-FDG PET/CT in metastases of papillary thyroid carcinoma. Endocrine. 2021;73:767–8. https://doi.org/10.1007/s12020-021-02668-3.CrossRefPubMed

14.

Fu H, Fu J, Huang J, Su X, Chen H. 68Ga-FAPI PET/CT in thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy. Clin Nucl Med. 2021;46:427–30. https://doi.org/10.1097/RLU.0000000000003569.CrossRefPubMed

15.

Chen Y, Zheng S, Zhang J, Yao S, Miao W. (68)Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. Ann Nucl Med. 2022;36:610–22. https://doi.org/10.1007/s12149-022-01742-8.CrossRefPubMed

16.

Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, et al. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575–84. https://doi.org/10.1007/s11307-015-0866-0.CrossRefPubMedPubMedCentral

17.

Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S, et al. [(18)F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49:2761–73. https://doi.org/10.1007/s00259-022-05758-0.CrossRefPubMed

18.

Liu T, Liu C, Xu X, Liu F, Guo X, Li N, et al. Preclinical evaluation and pilot clinical study of Al(18)F-PSMA-BCH for prostate cancer PET imaging. J Nucl Med Off Publ Soc Nucl Med. 2019;60:1284–92. https://doi.org/10.2967/jnumed.118.221671.CrossRef

19.

Hu K, Li J, Wang L, Huang Y, Li L, Ye S, et al. Preclinical evaluation and pilot clinical study of [(18)F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts. Acta Pharm Sin B. 2022;12:867–75. https://doi.org/10.1016/j.apsb.2021.09.032.CrossRefPubMed

20.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed

21.

Wang S, Zhou X, Xu X, Ding J, Liu S, Hou X, et al. Clinical translational evaluation of Al(18)F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021;48:4259–71. https://doi.org/10.1007/s00259-021-05470-5.CrossRefPubMed

22.

Maisto C, Aurilio M, Morisco A, de Marino R, Buonanno Recchimuzzo MJ, Carideo L, et al. Analysis of pros and cons in using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007: production, costs, and PET/CT applications in patients with prostate cancer. Molecules (Basel, Switzerland). 2022:27. https://doi.org/10.3390/molecules27123862.

23.

Qichang W, Lin B, Gege Z, Youjia Z, Qingjie M, Renjie W, et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol. 2019;181:93–102. https://doi.org/10.1530/EJE-19-0261.CrossRefPubMed

24.

Pure E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors? Cancer Immunol Res. 2016;4:269–78. https://doi.org/10.1158/2326-6066.CIR-16-0011.CrossRefPubMedPubMedCentral

25.

Gulec SA, Kuker RA, Goryawala M, Fernandez C, Perez R, Khan-Ghany A, et al. (124)I PET/CT in patients with differentiated thyroid cancer: clinical and quantitative image analysis. Thyroid. 2016;26:441–8. https://doi.org/10.1089/thy.2015.0482.CrossRefPubMed

26.

Freudenberg LS, Jentzen W, Muller SP, Bockisch A. Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging. 2008;35:502–8. https://doi.org/10.1007/s00259-007-0601-4.CrossRefPubMed

27.

Wu D, Plyku D, Kulkarni K, Garcia C, Atkins F, Tefera E, et al. Optimal time for 124I PET/CT imaging in metastatic differentiated thyroid cancer. Clin Nucl Med. 2021;46:283–8. https://doi.org/10.1097/RLU.0000000000003505.CrossRefPubMed

28.

Ham J, Wang B, Po JW, Singh A, Niles N, Lee CS. Cancer-associated fibroblasts (CAFs) in thyroid papillary carcinoma: molecular networks and interactions. J Clin Pathol. 2021;74:759–65. https://doi.org/10.1136/jclinpath-2020-207357.CrossRefPubMed

29.

Jolly LA, Novitskiy S, Owens P, Massoll N, Cheng N, Fang W, et al. Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res. 2016;76:1804–13. https://doi.org/10.1158/0008-5472.CAN-15-2351.CrossRefPubMedPubMedCentral

30.

Shangguan C, Gan G, Zhang J, Wu J, Miao Y, Zhang M, et al. Cancer-associated fibroblasts enhance tumor (18)F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT. Theranostics. 2018;8:1376–88. https://doi.org/10.7150/thno.22717.CrossRefPubMedPubMedCentral

31.

Fujii T, Yajima R, Kurozumi S, Higuchi T, Obayashi S, Tokiniwa H, et al. Clinical significance of 18F-FDG-PET in Invasive lobular carcinoma. Anticancer Res. 2016;36:5481–5. https://doi.org/10.21873/anticanres.11129.CrossRefPubMed

32.

Yang T, Ma L, Hou H, Gao F, Tao W. FAPI PET/CT in the diagnosis of abdominal and pelvic tumors. Front Oncol. 2021;11:797960. https://doi.org/10.3389/fonc.2021.797960.CrossRefPubMed

Title: [18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT
Authors: Xingyu Mu
Xiaoxue Huang
Zewen Jiang
Meng Li
Lulu Jia
Zhongyuan Lv
Wei Fu
Jingsong Mao
Publication date: 10-12-2022
Publisher: Springer Berlin Heidelberg
Keywords: Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-06067-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

[¹⁸F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[¹⁸F]FDG PET/CT

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2023

The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies

Phantom-based evaluation of yttrium-90 datasets using biograph vision quadra

[68Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors’ density by immunochemistry techniques

Three-way multiplexing in prostate cancer patients — combining a bimodal sentinel node tracer with multicolor fluorescence imaging

Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma

EANM practice guideline for quantitative SPECT-CT